rs11739459 - GPBP1 - RMEL3
Magnitude 4.5 · 1 study on file
Reported associations
-
Class II HLA Variants Associate with Risk of Pegaspargase Hypersensitivity - Unknown journal (n.d.) · Unknown authors · PubMed 33768542
ABSTRACT: We conducted the first HLA allele and genome wide association study to identify loci associated with hypersensitivity reactions exclusively to the PEGylated preparation of asparaginase (pegaspargase) in racially diverse cohorts of pediatric leukemia patients: St. Jude Children's Research Hospital's Total XVI (TXVI, n = 598), Children's Oncology Group AALL0232 (n = 2472) and AALL0434 (n = 1189). Germline DNA was genotyped using arrays. Genetic variants not genotyped directly were imputed. HLA alleles were imputed using SNP2HLA or inferred using BWAkit. Analyses between genetic variants and hypersensitivity were performed in each cohort first using cohort-specific covariates and then combined using meta-analyses. Nongenetic risk factors included fewer intrathecal injections (
Auto-generated from study metadata. AI-synthesised commentary is added when this entry is regenerated through content-service's LLM mode.
Lifestyle context
Concrete actions anchored to the cited research. We do not prescribe, we describe.
Discuss with your doctor
-
Pegaspargase hypersensitivity risk with oncologist High
Variant rs11739459 is associated with increased hypersensitivity risk to pegaspargase, a chemotherapy used in acute lymphoblastic leukemia.
Inform oncologist before pegaspargase therapy; discuss premedication or alternative asparaginase formulations.